Sudeep Pharma Limited Stock Price Today (NSE: SUDEEPPHRM)

Sudeep Pharma Limited

SUDEEPPHRMPharmaceuticals
1197.10+53.10 (+4.64%)
Market Closed

Fundamental Score

...

Sudeep Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Sudeep Pharma Limited share price today is 1197.10, up +4.64% on NSE/BSE as of 22 September 2026. Sudeep Pharma Limited (SUDEEPPHRM) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of 13.52K (Cr). The 52-week high for SUDEEPPHRM share price is 1378.00 and the 52-week low is 524.05. At a P/E ratio of 72.73x, SUDEEPPHRM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 25.17% and a debt-to-equity ratio of 0.17.

Sudeep Pharma Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
1378.00
Low
978.45
Volume
3.0L
Change
+21.27%

Sudeep Pharma Limited share price chart: 21.27% return over the past month. 52-week high ₹1378.00, 52-week low ₹524.05.

Sudeep Pharma Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
1160.001165.001123.101144.0099.34K (Cr)
1107.201160.601107.201155.002.17L (Cr)
1107.201155.901086.201105.402.63L (Cr)
1125.801128.801085.601107.205.35L (Cr)
1238.001238.001142.701142.701.25L (Cr)
1152.901244.001152.901202.805.93L (Cr)
1226.001259.801213.501213.502.84L (Cr)
1354.201363.001277.001277.303.19L (Cr)
1327.001362.901311.101344.201.92L (Cr)
1342.501378.001305.001323.302.08L (Cr)

Sudeep Pharma Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
1222.701378.001085.601144.00-6.44%
893.501209.70801.401209.70+35.39%
851.95909.00788.35881.05+3.42%
772.85882.40721.10848.50+9.79%
710.00742.15624.70742.15+4.53%
604.00728.00596.00707.55+17.14%
607.40653.55552.05592.55-2.44%
592.15688.00583.00638.95+7.90%
602.75645.00524.05609.15+1.06%
782.00786.90601.05602.75-22.92%
730.00795.00725.00774.15+6.05%

Returns & Performance

Excellent

Return on Equity (ROE)

25.17%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

28.18%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

31.79%

Average operating profit margin over 5 years

Dividend Yield

0.18%

Annual dividend as % of current share price

Sudeep Pharma Limited Valuation Check

Poor

Price to Earnings (P/E)

72.73x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

76.15%

% shares held by company founders/management

Poor

FII Holding

1.55%

% shares held by foreign institutional investors

Good

DII Holding

18.11%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

10.61%

Net profit growth vs same quarter last year

Average

Revenue Growth (Quarterly YoY)

15.73%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

24.45%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-42.14%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

39.04%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.17x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

30.99x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-125.74 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Sudeep Pharma Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SUDEEPPHRM across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Strong Return on Equity (25.17%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (28.18%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (31.79%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Strong Revenue Growth (15.73%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (24.45% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Strong Profit Growth Track Record (39.04% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.17)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (30.99x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 3.09)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Premium Valuation Risk (P/E: 72.73x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

High Price-to-Book Ratio (15.31x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Weak Earnings Growth (-42.14% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Negative Free Cash Flow (₹-125.74 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Sudeep Pharma Limited vs Pharmaceuticals Peers

Peer Comparison -

Compare Sudeep Pharma Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
60.5/100
1197
₹13521.12
72.7
Average
25.17%
Excellent
28.18%
Excellent
0.2
Excellent
39.04%
Excellent
24.45%
Excellent
0.18%
66.4/100
1865
₹447445.46
37.0
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9488
₹251432.00
86.1
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1127
₹112514.52
25.1
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1363
₹110118.03
32.7
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1937
₹104646.43
95.6
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1699
₹97754.71
26.5
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96022.50
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95607.50
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2265
₹93544.50
45.8
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Sudeep Pharma Limited Quarterly Performance

Latest quarterly metrics for SUDEEPPHRM — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

15.73%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

10.61%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

24.45%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

39.04%

Compounded annual net profit growth over 5 years

Sudeep Pharma Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for SUDEEPPHRM — calculated from daily price history

76RSI 14
Overbought — RSI 76

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
1004
▲ Price above SMA 50 — Short-term bullish
30-Day Avg Volume
355K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Sudeep Pharma Limited Financial Statements

Annual income statement, balance sheet and cash flow for Sudeep Pharma Limited (SUDEEPPHRM) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Sudeep Pharma Limited

Loading latest quarterly results...

About SUDEEPPHRM (Sudeep Pharma Limited)

Sudeep Pharma Limited (SUDEEPPHRM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with ...a current market capitalisation of ₹13.52K (Cr). Sudeep Pharma Limited has delivered a Return on Equity (ROE) of 25.17% and a ROCE of 28.18%. The debt-to-equity ratio stands at 0.17, reflecting the company's capital structure. Investors tracking SUDEEPPHRM share price can monitor key metrics including P/E ratio, promoter holding of 76.15%, and quarterly earnings growth.

Company Details

Symbol:SUDEEPPHRM
Industry:Pharmaceuticals
Sector:N/A
Website:N/A

SUDEEPPHRM Share Price: Frequently Asked Questions

What is the current share price of Sudeep Pharma Limited?

Sudeep Pharma Limited (SUDEEPPHRM) trades at ₹1197.10 on NSE and BSE. Market cap ₹13.52K (Cr). Educational data only.

What is the P/E ratio of Sudeep Pharma Limited?

Sudeep Pharma Limited has a P/E of 72.73x vs industry average 34.89x.

What is the Bull Run score for Sudeep Pharma Limited?

Sudeep Pharma Limited has a Bull Run score of 60.5/100 based on 25+ financial parameters.

Does Sudeep Pharma Limited pay dividends?

Sudeep Pharma Limited has a dividend yield of 0.18%. Past dividends don't guarantee future payments.

What is the ROE of Sudeep Pharma Limited?

Sudeep Pharma Limited has ROE of 25.17%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Sudeep Pharma Limited?

Sudeep Pharma Limited has debt-to-equity of 0.17.

Is Sudeep Pharma Limited a good investment?

Bull Run gives Sudeep Pharma Limited a score of 60.5/100. This is not investment advice — consult a SEBI-registered advisor.